Form 4 Sarepta Therapeutics, For: Apr 20 Filed by: Kaye Edward M. MD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
April 25, 2016 7:02 AM EDTSarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.
After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.
... More
